Aug 3, 2026 07:03AM
Aug 3, 2026 07:00AM
Jul 29, 2026 07:30AM
Jul 6, 2026 07:31AM
Jul 6, 2026 07:30AM
Jun 9, 2026 07:30AM
Jun 9, 2026 07:30AM TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
Jun 3, 2026 07:30AM
Jun 3, 2026 07:30AM
Jun 2, 2026 07:30AM
Jun 1, 2026 07:30AM
Jun 1, 2026 07:30AM
May 28, 2026 07:30AM
May 27, 2026 07:31AM TG Therapeutics reports positive phase 3 trial for simplified BRIUMVI dosing
May 27, 2026 07:30AM
May 26, 2026 07:30AM
May 26, 2026 07:30AM
May 6, 2026 07:00AM
Apr 30, 2026 07:30AM
Apr 22, 2026 07:32AM
Apr 22, 2026 07:30AM TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Apr 15, 2026 07:30AM
Apr 15, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 19, 2026 07:30AM
Mar 9, 2026 07:31AM
Mar 9, 2026 07:30AM
Mar 6, 2026 07:31AM TG Therapeutics to present BRIUMVI data at neurology meeting
Mar 6, 2026 07:30AM
Feb 26, 2026 07:00AM
Feb 23, 2026 07:30AM
Feb 17, 2026 07:30AM
Feb 8, 2026 04:17PM
Feb 6, 2026 07:30AM
Feb 6, 2026 07:30AM TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Jan 27, 2026 07:32AM
Jan 27, 2026 07:30AM
Jan 13, 2026 04:25PM
Jan 13, 2026 04:25PM
Jan 7, 2026 07:30AM
Nov 28, 2025 07:30AM
Nov 19, 2025 08:30AM TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
Nov 10, 2025 04:00PM
Nov 3, 2025 07:00AM
Oct 31, 2025 07:30AM
Oct 28, 2025 07:30AM
Oct 28, 2025 07:30AM
Sep 24, 2025 09:10AM
Sep 24, 2025 09:10AM New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
Sep 10, 2025 07:30AM

1,177,143 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All